Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders

a technology of inflammatory and autoimmune disorders and biological markers, applied in the field of human disease treatment, can solve the problems of limited applicability of biological markers in many patients, lack of accurate but simple methods for evaluating drug efficacy, and limited data available in vivo relating to other measurements

Inactive Publication Date: 2005-01-06
PPD BIOMARKER DISCOVERY SCI
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

In an alternative embodiment, the present invention provides a method for detecting a systemic effect of an anti-inflammatory drug (e.g., a glucocorticoid such as prednisone) in a subject. In this method, a biological sample correlated with systemic activity, such as blood or urine, is obtained from the subject. Next, a set of factors including at least one of the inventive biomarkers is measured in the biological sample. The measured values are t

Problems solved by technology

In addition, because of their broad-ranging systemic effects, prednisone and other glucocorticoids have a large number of side effects, some of them quite serious, which restrict their applicability in many patients, particularly for long-term use.
However, while many studies examine IgE levels and related factors, there are few data available with respect to other measurements in vivo, such a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders

Examples

Experimental program
Comparison scheme
Effect test

example

Effect of Prednisone on Biological Markers of Atopy and Asthma

Methods

The inventive biomarkers were identified in a study of the effects of oral prednisone on biological markers of allergy and asthma. Eighty subjects were enrolled in the study, 23 with atopic asthma, 28 with allergy alone, 26 with neither allergy nor asthma (healthy controls), and 3 with asthma alone. Allergy was defined by a positive skin prick test. Mild asthma was defined as positive methacholine challenge within the last three months, as well as one or more of documented diagnosis of asthma, history of cough, recurrent wheeze, recurrent difficult breathing, and recurrent chest tightening. Approximately half of the subjects from each disease group were given oral prednisone for three days, while the other half was given a placebo. Blood samples were taken before treatment and after three days of treatment with oral prednisone or placebo.

Cellular markers in the blood samples were evaluated using the SurroScan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Novel biological markers indicative of the action of an anti-inflammatory or immunosuppressive drug can be used to evaluate drug efficacy and compare local and systemic drug effects. They can also aid in comparison of different drugs, doses, and delivery routes. The biological markers include cell populations, cell surface antigen expression levels, and soluble factor concentrations. Measurement values of the novel biomarkers were shown to change significantly in allergic, atopic asthmatic, and healthy subjects after administration of prednisone.

Description

FIELD OF THE INVENTION The present invention relates generally to treatment of disease in humans and other mammals. More particularly, it relates to biological markers such as cell populations, cell surface antigen expression levels, and soluble factor concentrations that are indicative of the efficacy of treatment of atopic asthma and other inflammatory disorders. BACKGROUND OF THE INVENTION Prednisone is a corticosteroid used to treat a wide variety of inflammatory disorders, including asthma, atopy, arthritis, multiple sclerosis, ulcerative colitis, and Crohn's disease. While a comprehensive understanding of the action of prednisone and other glucocorticoids (a class of corticosteroids) is lacking, the drugs are known to have broad-ranging anti-inflammatory and immunosuppressive effects, including inhibition of pro-inflammatory mediators and activation of anti-inflammatory mediators. They affect the growth, differentiation, and function of monocytes and lymphocytes; the distrib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/50
CPCG01N33/5008G01N33/5023G01N33/5047G01N33/505G01N2800/52G01N33/5082G01N33/5088G01N33/5094G01N2333/70535G01N33/5052
Inventor ALTERS, SUSAN E.CHEAL, KAREN L.KANTOR, AARON B.
Owner PPD BIOMARKER DISCOVERY SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products